Month: August 2018

Antibody Discovery: The Rise of Services and Platform Providers

Owing to several beneficial features, such as high specificity, and a favorable safety profile, antibody (Ab) discovery based pharmacological interventions, with 79 molecules approved till date and over 200 molecules in the preclinical / discovery stages, presently represent the largest class of biologics. The discovery of antibodies is a long, arduous and cost intensive process.

Non-Opioids Chronic Pain Management Drugs and Devices: Future Roadmap to USD 10 Billion+ Opportunity

Owing to the rapid onset of their medicinal effect, which offers immediate relief with high efficacy, opioids are still considered to be one of the most widely used pharmacological interventions for the management of moderate to severe forms of pain. However, these drugs are known to induce a euphoric state upon intake, often causing patients